

Transfer of Amoéba's shares to the Euronext Growth Paris market

Chassieu, September 10, 2020, 8:45 am – AMOEBEBA (FR0011051598) - producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the transfer of the listing of its shares from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility.

The application for the admission of Amoéba's shares to the Euronext Growth market in Paris was approved by the Euronext Admissions Committee on September 7, 2020.

As indicated in the company's previous press releases, this transfer will enable Amoéba to be listed on a market more suited to its size and market capitalization. It should also simplify the Company's operations and reduce the costs related to its listing, while allowing it to continue to benefit from the attractions of the financial markets.

Amoéba will continue to provide accurate, precise and truthful information, making public any inside information concerning the company, in accordance with the European Regulation on Market Abuse (MAR Regulation).

The information document prepared in connection with this transfer is available online on the company's website www.amoeba-biocide.com under the heading "Investors / Regulatory information and financial documents / other information".

Amoéba has chosen Portzamparc BNP Paribas as Listing Sponsor to accompany it on the Euronext Growth Paris market.

The ISIN share identification code remains unchanged (FR0011051598) and the mnemonic code becomes ALMIB. In addition, the holding of Amoéba shares remains eligible for PEAs and PEA-SMEs

Definitive timetable for the transfer of listing market

September 10, 2020 before market opening:

- Distribution of a Euronext notice announcing the delisting of the company's shares from Euronext Paris
- Distribution of a Euronext notice announcing the listing of the company's shares on Euronext Growth Paris

September 14, 2020 :

- Delisting of Amoéba's shares on Euronext Paris (before market opening)



- Listing of Amoéba's shares on Euronext Growth Paris (at the opening)



About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba

Valérie FILIATRE

General Manager

+33 4 26 69 16 00

valerie.filiatre@amoeba-biocide.com

Investors and Media Relations

Grégory BOSSON / Mathieu CALLEUX

Agence Calyptus

+33(0)1 53 65 37 90

amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the Universal Registration Document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 30, 2020 under number D20-0416 (a copy of which is available on www.amoeba-biocide.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.